BR0009485A - Método e composições para evitar ou reduzir infecção por hiv pelo uso de inibidores para leucina aminopeptidase - Google Patents

Método e composições para evitar ou reduzir infecção por hiv pelo uso de inibidores para leucina aminopeptidase

Info

Publication number
BR0009485A
BR0009485A BR0009485-4A BR0009485A BR0009485A BR 0009485 A BR0009485 A BR 0009485A BR 0009485 A BR0009485 A BR 0009485A BR 0009485 A BR0009485 A BR 0009485A
Authority
BR
Brazil
Prior art keywords
compositions
leucine aminopeptidase
inhibitors
lapase
preventing
Prior art date
Application number
BR0009485-4A
Other languages
English (en)
Inventor
Gabriel Pulido-Cejudo
Original Assignee
Canbreal Therodiagnostics Ca
Mini Health Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canbreal Therodiagnostics Ca, Mini Health Canada filed Critical Canbreal Therodiagnostics Ca
Publication of BR0009485A publication Critical patent/BR0009485A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

"MéTODO E COMPOSIçõES PARA EVITAR OU REDUZIR INFECçãO POR HIV PELO USO DE INIBIDORES PARA LEUCINA AMINOPEPTIDASE". A despeito de se ter alcançado uma profunda e compreensiva estrutura genética do vírus da imunodeficiência humana (HIV) e a de seus vários grupamentos estruturais e geográficos, um sucesso muito limitado na prevenção e tratamento de AIDS foi alcançado. é descrito aqui um método para evitar ou reduzir infectuosidade por HIV pela utilização de um anticorpo específico para leucina aminopeptidase estimulada por estrogênio (es-LAPase), ou um ou mais inibidores da atividade de LAPase, ou uma combinação deles. Também é descrito um método para evitar ou reduzir infectuosidade por HIV pela utilização de um anticorpo específico para es-LAPase, um ou mais inibidores da atividade de es-LAPase e um composto anti-estrogênio. Novas composições são também definidas.
BR0009485-4A 1999-03-30 2000-03-30 Método e composições para evitar ou reduzir infecção por hiv pelo uso de inibidores para leucina aminopeptidase BR0009485A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002267481A CA2267481A1 (en) 1999-03-30 1999-03-30 Critical interdependency: from the role of estrogen on breast cancer to the susceptibility of women towards hiv infection
PCT/CA2000/000331 WO2000059534A1 (en) 1999-03-30 2000-03-30 Method and compositions for preventing or reducing hiv infection by use of inhibitors for leucine aminopeptidase

Publications (1)

Publication Number Publication Date
BR0009485A true BR0009485A (pt) 2002-02-05

Family

ID=4163415

Family Applications (3)

Application Number Title Priority Date Filing Date
BR0009484-6A BR0009484A (pt) 1999-03-30 2000-03-30 Imunoensaio em série para câncer
BR0009483-8A BR0009483A (pt) 1999-03-30 2000-03-30 Anticorpo monoclonal contra leucina aminopeptidase estimulada por estrogênio
BR0009485-4A BR0009485A (pt) 1999-03-30 2000-03-30 Método e composições para evitar ou reduzir infecção por hiv pelo uso de inibidores para leucina aminopeptidase

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BR0009484-6A BR0009484A (pt) 1999-03-30 2000-03-30 Imunoensaio em série para câncer
BR0009483-8A BR0009483A (pt) 1999-03-30 2000-03-30 Anticorpo monoclonal contra leucina aminopeptidase estimulada por estrogênio

Country Status (8)

Country Link
US (4) US6406701B1 (pt)
EP (3) EP1114064A1 (pt)
CN (3) CN1382059A (pt)
AU (3) AU3413100A (pt)
BR (3) BR0009484A (pt)
CA (1) CA2267481A1 (pt)
MX (3) MXPA01010985A (pt)
WO (3) WO2000059534A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10054899C2 (de) 2000-12-08 2003-08-21 Tubag Trass Zement Stein Vorrichtung und Verfahren zum Aufbringen von Dünnbettmörtel
AU2002230049A1 (en) * 2001-01-30 2002-08-12 The Provost, Fellows And Scholars Of The College Of The Holy And Unidivided Trinity Of Queen Elizabe Thioredoxin derived from h. pylori, which is capable of inhibiting nf-kappa b activation
EP2341350B1 (en) * 2003-09-20 2017-11-08 Electrophoretics Limited Diagnostic method for brain damage-related disorders based on detection of dj-1
GB0404419D0 (en) 2004-02-27 2004-03-31 Intelligent Textiles Ltd Electrical components and circuits constructed as textiles
US7197427B2 (en) * 2004-03-31 2007-03-27 Genworth Financial Inc. Method for risk based testing
EP2270512B1 (en) * 2004-12-08 2016-03-23 Cedars-Sinai Medical Center Methods for diagnosis of Crohn's disease
CN100376680C (zh) * 2005-11-01 2008-03-26 暨南大学 双重靶效应基因嵌合重组体及其构建方法和应用
DE102006023535B4 (de) * 2006-05-19 2008-12-18 Keiper Gmbh & Co.Kg Getriebestufe für einen Stellantrieb
US20100021917A1 (en) * 2007-02-14 2010-01-28 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2010039931A2 (en) * 2008-10-01 2010-04-08 Cedars-Sinai Medical Center Methods of using il17rd and il23-il17 pathway genes to diagnose crohn's disease
WO2008137762A2 (en) * 2007-05-04 2008-11-13 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
US20100184050A1 (en) * 2007-04-26 2010-07-22 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20080318063A1 (en) * 2007-06-22 2008-12-25 Anderson Jerrel C Glass laminates with improved weatherability
US20110104121A1 (en) * 2008-05-21 2011-05-05 Wira Charles R Female Reproductive Tract and Anal Prophylaxes
US20110189685A1 (en) * 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
WO2010075579A2 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
KR20210157418A (ko) 2013-03-27 2021-12-28 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
WO2015133935A1 (ru) * 2014-03-04 2015-09-11 Григорий Дмитриевич КАМИНСКИЙ Способ и устройство прогнозирования времени развития вич-инфекции у женщин после родов
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
BR112018010317A2 (pt) 2015-12-18 2018-12-04 Intelligent Textiles Ltd tecido condutor, método de fabricação de um tecido condutor, sistema para o mesmo e artigo de vestuário
EP3430172A4 (en) 2016-03-17 2019-08-21 Cedars-Sinai Medical Center METHOD FOR DIAGNOSIS OF INFLAMMATORY ENDURANCE THROUGH RNASET2

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5678600A (en) * 1979-12-03 1981-06-27 Eiken Kagaku Kk Method for measuring activity of leucine aminopeptidase in serum
US5001052A (en) * 1989-02-09 1991-03-19 Wisconsin Alumni Research Foundation Immunoassay for FHAP and antibody useful therewith
US5179008A (en) * 1989-02-09 1993-01-12 Wisconsin Alumni Research Foundation Hybridoma and monoclonal antibody to FHAP
CA2108533C (en) * 1992-10-16 2002-10-08 Gabriel Pulido-Cejudo Monoclonal antibodies directed against ndp-kinase
AU2681997A (en) * 1996-04-26 1997-11-19 Children's Medical Center Corporation Non-invasive enzyme screen for tissue remodelling-associated conditions

Also Published As

Publication number Publication date
CA2267481A1 (en) 2000-09-30
AU3413200A (en) 2000-10-23
EP1113812A1 (en) 2001-07-11
CN1382059A (zh) 2002-11-27
US6521415B1 (en) 2003-02-18
WO2000060357A1 (en) 2000-10-12
US6406701B1 (en) 2002-06-18
BR0009483A (pt) 2002-02-05
AU3546400A (en) 2000-10-23
AU3413100A (en) 2000-10-23
MXPA01010985A (es) 2002-06-04
US20040106143A1 (en) 2004-06-03
MXPA01010984A (es) 2002-06-04
WO2000059534A1 (en) 2000-10-12
CN1362970A (zh) 2002-08-07
CN1351714A (zh) 2002-05-29
EP1114322A1 (en) 2001-07-11
BR0009484A (pt) 2002-02-05
EP1114064A1 (en) 2001-07-11
WO2000059944A1 (en) 2000-10-12
MXPA01010995A (es) 2002-06-04
US6649743B1 (en) 2003-11-18

Similar Documents

Publication Publication Date Title
BR0009485A (pt) Método e composições para evitar ou reduzir infecção por hiv pelo uso de inibidores para leucina aminopeptidase
GEP20084497B (en) Hiv protease inhibitors
RU2325389C2 (ru) Композиция и производные замещенного азаиндолоксоацетапиперазина, обладающие противовирусной активностью
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
HUP0103319A2 (hu) Készítmények HIV- és egyéb vírusfertőzések kezelésére és alkalmazásuk
FI921030A (fi) Cykliska ureaderivat, dessa foereningar innehaollande laekemedel och foerfarande foer deras framstaellning
DK0763017T3 (da) N-(3-amino-2-hydroxybutyl)sulfonamidderivater som HIV-proteaseinhibitorer
NO985821D0 (no) Substituerte cyklopentanforbindelser som er nyttige som neuramidaseinhibitorer
BR0111678A (pt) Composições medicinais contendo derivados de propenona
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
EA200400690A1 (ru) Нуклеозиды, их препараты и их применение в качестве ингибиторов вирусных рнк-полимераз
ATE179164T1 (de) Hiv-proteaseinhibitoren
PE61699A1 (es) Composicion farmaceutica de lamivudina
ES2105923B1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
DE60005517D1 (de) Kaliumkanal-blockierende mittel
EA200201024A1 (ru) Фармацевтические композиции, содержащие олигосахариды, и их получение
DE69828522D1 (de) Antithrombotische mittel
DK1411956T3 (da) Anvendelse af oversulfaterede polysaccharider som inhibitorer af HIV
MX9203068A (es) Compuestos activirales oralmente activos.
MY117535A (en) Hiv protease inhibitors
IT1318424B1 (it) Composti con attivita' anti-hiv.
ATE259802T1 (de) Verbindungen mit antithrombotischer wirkung
CA2303591A1 (en) Method and compositions for preventing or reducing hiv infection
ATE268768T1 (de) Antithrombosemittel
DE60011096D1 (de) Ester enthaltende zusammensetzungen zur behandlung von parasitischem befall in organismen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1942 DE 25/03/2008 POR TER SIDO INDEVIDO.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10 (VIII), 13 E 24 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.